...
rytm-img

Rhythm Pharmaceuticals Inc, Common Stock

RYTM

NMQ

$55.24

-$0.44

(-0.79%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$3.42B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
519.16K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
2.09
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$35.17 L
$68.58 H
$55.24

About Rhythm Pharmaceuticals Inc, Common Stock

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameRYTMSectorS&P500
1-Week Return-6.2%-2.27%-0.57%
1-Month Return-8.04%-3.96%1.21%
3-Month Return11.33%-9.7%7.57%
6-Month Return24.5%-3.37%11.45%
1-Year Return32.66%3.71%28.48%
3-Year Return444.77%3.8%29.52%
5-Year Return133.97%39.78%90.66%
10-Year Return84.13%106.91%203.75%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-35.00K3.15M23.64M77.43M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":0.05,"profit":true},{"date":"2021-12-31","value":4.07,"profit":true},{"date":"2022-12-31","value":30.53,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue834.00K690.00K599.00K2.13M9.30M[{"date":"2019-12-31","value":8.97,"profit":true},{"date":"2020-12-31","value":7.42,"profit":true},{"date":"2021-12-31","value":6.44,"profit":true},{"date":"2022-12-31","value":22.93,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit(834.00K)(690.00K)2.56M21.50M68.13M[{"date":"2019-12-31","value":-1.22,"profit":false},{"date":"2020-12-31","value":-1.01,"profit":false},{"date":"2021-12-31","value":3.75,"profit":true},{"date":"2022-12-31","value":31.57,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin(Infinity%)(1971.43%)81.01%90.98%87.99%[{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":-2166.97,"profit":false},{"date":"2021-12-31","value":89.04,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":96.71,"profit":true}]
Operating Expenses146.00M136.57M172.61M200.66M252.48M[{"date":"2019-12-31","value":57.83,"profit":true},{"date":"2020-12-31","value":54.09,"profit":true},{"date":"2021-12-31","value":68.37,"profit":true},{"date":"2022-12-31","value":79.48,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(146.00M)(136.57M)(170.06M)(179.16M)(184.36M)[{"date":"2019-12-31","value":-14600000000,"profit":false},{"date":"2020-12-31","value":-13657500000,"profit":false},{"date":"2021-12-31","value":-17005900000,"profit":false},{"date":"2022-12-31","value":-17915700000,"profit":false},{"date":"2023-12-31","value":-18435700000,"profit":false}]
Total Non-Operating Income/Expense10.54M5.16M100.89M(3.13M)1.06M[{"date":"2019-12-31","value":10.45,"profit":true},{"date":"2020-12-31","value":5.11,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-3.11,"profit":false},{"date":"2023-12-31","value":1.05,"profit":true}]
Pre-Tax Income(140.73M)(134.00M)(69.61M)(181.12M)(184.11M)[{"date":"2019-12-31","value":-14072900000,"profit":false},{"date":"2020-12-31","value":-13399600000,"profit":false},{"date":"2021-12-31","value":-6961200000,"profit":false},{"date":"2022-12-31","value":-18111900000,"profit":false},{"date":"2023-12-31","value":-18411400000,"profit":false}]
Income Taxes(6.11M)(3.27M)(1.60M)1.96M564.00K[{"date":"2019-12-31","value":-311.16,"profit":false},{"date":"2020-12-31","value":-166.62,"profit":false},{"date":"2021-12-31","value":-81.8,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":28.75,"profit":true}]
Income After Taxes(134.62M)(130.73M)(68.01M)(183.08M)(184.68M)[{"date":"2019-12-31","value":-13462400000,"profit":false},{"date":"2020-12-31","value":-13072700000,"profit":false},{"date":"2021-12-31","value":-6800700000,"profit":false},{"date":"2022-12-31","value":-18308100000,"profit":false},{"date":"2023-12-31","value":-18467800000,"profit":false}]
Income From Continuous Operations(140.73M)(134.00M)(69.61M)(181.12M)(185.54M)[{"date":"2019-12-31","value":-14072900000,"profit":false},{"date":"2020-12-31","value":-13399600000,"profit":false},{"date":"2021-12-31","value":-6961200000,"profit":false},{"date":"2022-12-31","value":-18111900000,"profit":false},{"date":"2023-12-31","value":-18553800000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(134.62M)(130.73M)(68.01M)(183.08M)(184.68M)[{"date":"2019-12-31","value":-13462400000,"profit":false},{"date":"2020-12-31","value":-13072700000,"profit":false},{"date":"2021-12-31","value":-6800700000,"profit":false},{"date":"2022-12-31","value":-18308100000,"profit":false},{"date":"2023-12-31","value":-18467800000,"profit":false}]
EPS (Diluted)(3.90)(3.05)(3.41)(3.48)(3.20)[{"date":"2019-12-31","value":-390,"profit":false},{"date":"2020-12-31","value":-305,"profit":false},{"date":"2021-12-31","value":-341,"profit":false},{"date":"2022-12-31","value":-348,"profit":false},{"date":"2023-12-31","value":-320,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

RYTM
Cash Ratio 3.06
Current Ratio 3.49
Quick Ratio 3.34

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

RYTM
ROA (LTM) -46.24%
ROE (LTM) -147.90%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

RYTM
Debt Ratio Lower is generally better. Negative is bad. 0.97
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.03

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

RYTM
Trailing PE NM
Forward PE NM
P/S (TTM) 30.41
P/B 313.18
Price/FCF NM
EV/R 28.60
EV/Ebitda NM

FAQs

What is Rhythm Pharmaceuticals Inc share price today?

Rhythm Pharmaceuticals Inc (RYTM) share price today is $55.24

Can Indians buy Rhythm Pharmaceuticals Inc shares?

Yes, Indians can buy shares of Rhythm Pharmaceuticals Inc (RYTM) on Vested. To buy Rhythm Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in RYTM stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Rhythm Pharmaceuticals Inc be purchased?

Yes, you can purchase fractional shares of Rhythm Pharmaceuticals Inc (RYTM) via the Vested app. You can start investing in Rhythm Pharmaceuticals Inc (RYTM) with a minimum investment of $1.

How to invest in Rhythm Pharmaceuticals Inc shares from India?

You can invest in shares of Rhythm Pharmaceuticals Inc (RYTM) via Vested in three simple steps:

  • Click on Sign Up or Invest in RYTM stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Rhythm Pharmaceuticals Inc shares
What is Rhythm Pharmaceuticals Inc 52-week high and low stock price?

The 52-week high price of Rhythm Pharmaceuticals Inc (RYTM) is $68.58. The 52-week low price of Rhythm Pharmaceuticals Inc (RYTM) is $35.17.

What is Rhythm Pharmaceuticals Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Rhythm Pharmaceuticals Inc (RYTM) is

What is Rhythm Pharmaceuticals Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Rhythm Pharmaceuticals Inc (RYTM) is 313.18

What is Rhythm Pharmaceuticals Inc dividend yield?

The dividend yield of Rhythm Pharmaceuticals Inc (RYTM) is 0.00%

What is the Market Cap of Rhythm Pharmaceuticals Inc?

The market capitalization of Rhythm Pharmaceuticals Inc (RYTM) is $3.42B

What is Rhythm Pharmaceuticals Inc’s stock symbol?

The stock symbol (or ticker) of Rhythm Pharmaceuticals Inc is RYTM

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top